ArticleJACC. Case reports2026
Left Ventricular Metastasis from Hepatocellular Carcinoma Presenting With Systemic Embolization and Stroke.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac metastases are more common than primary cardiac tumors but are often unrecognized. Hepatocellular carcinoma (HCC) rarely involves the heart, typically affecting the right atrium. Left ventricular (LV) involvement is extremely rare and may cause systemic embolization. CASE SUMMARY: A 71-year-old man with prior HCC presented with acute stroke symptoms. Neuroimaging revealed multifocal acute infarcts. Computed tomography revealed a psoas mass and splenic and renal infarcts, raising concern for malignancy-associated embolization. Transthoracic echocardiography identified an LV mass initially suspected as thrombus. Cardiac magnetic resonance imaging (CMR) supported metastatic tumor. Psoas biopsy confirmed recurrent HCC. The patient was started on nivolumab and ipilimumab with planned radiation. DISCUSSION: HCC can rarely metastasize to the LV and present with systemic embolization. Multimodality imaging, particularly CMR, is critical for diagnosis and management. TAKE-HOME MESSAGES: LV metastasis from HCC, although rare, may present with systemic embolization. CMR is key to distinguishing tumor from thrombus and guiding management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.